Trim IBM 25% in tranches at $230-235 and $240-245; retain 70-75% residual core with $215 hard stop
Do not initiate new longs near current levels; explicit exit triggers for residual core: (1) fraud escalation, (2) Q3 miss with guidance reset, (3) close below $200, or (4) dividend cut. Rating capped at Underweight (not full Sell) due to quantitative FCF floor ($12B TTM, 1.9x dividend coverage), defensive ballast (0.705 beta, active deleveraging, 20+ year dividend history), and Q3 2026 earnings binary catalyst.
| Position | Action |
|---|---|
| Now (executable at market) | Trim 15% of position |
| Price reaches declining 50 SMA ($246.63) on declining volume | Trim additional 10% of position at $240-245 |
| Residual core retained | Hold 70-75% for dividend yield (4.4%+), FCF coverage (1.9x), and defensive beta (0.705) |
IBM is a quality compounder at a discount, with catalysts that are dated, funded, and verifiable—the risk/reward is quietly tipping bullish for patient capital over a 6-12 month horizon.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | $262.64 | bearish |
| 50 SMA | $246.63 | bearish |
| 10 EMA | $233.51 | neutral |
| RSI (14) | 48.65 | neutral |
| MACD Line | -1.79 | bearish |
| MACD Signal | -3.59 | bearish |
| MACD Histogram | +1.80 | bullish |
| Bollinger Middle Band | $229.73 | neutral |
| Bollinger Upper Band | $245.07 | bearish |
| Bollinger Lower Band | $214.40 | bullish |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price reaches declining 50 SMA ($246.63) on declining volume
Then: Trim additional 10% at $240-245
EV: ~+$8.50 from current price of $233.69 · concedes: Not arguing IBM is a screaming buy today at $233.69; Bear market structure is acknowledged (price below 50 SMA $246.63 and 200 SMA $262.64, all MAs stacked bearishly); Securities fraud inquiry taken seriously; multiple expansion is dead until resolution; Technical analysis report called for HOLD and that is respected for today; The strategy is to scale in on weakness toward $220-$225, not buy aggressively at current levels
IBM is a value trap with a quantum narrative bolted on—not a quality compounder at a discount. The stock requires four or more independent positive catalysts (fraud resolution, quantum momentum, FedRAMP conversion, mainframe stabilization, macro cooperation) to work, while the bear case requires only one or two things to go wrong.
EV: -$3.30 · concedes: MACD did flip from -9.77 to +1.80 (bullish signal acknowledged); Forward PE of 17.75 exists as stated; PEG ratio of 2.41 was cited (though interpreted as showing IBM is expensive for its growth profile); ATR of $8.25 noted as elevated volatility; 8% recession probability acknowledged (though characterized as insufficient protection given IBM's discretionary capex exposure); Beta of 0.705 acknowledged (though noted it caps upside as well as cushions downside)
→ vs conservative: Waiting for 'cleaner structural confirmation' is capitulation disguised as discipline; the setup IS the confirmation and by the time the clean signal arrives, you'll be selling at $215 not $240
→ vs conservative: Price below 50 and 200 SMA with MACD negative and two -25% air pockets in twelve months is sufficient confirmation
→ vs neutral: Risk-reward is not 'balanced' at $233; the downside tail is empirically validated with two documented -25% events while the bull case has only a 2029 roadmap with zero near-term EPS impact
→ vs neutral: Long-duration narrative trade with FedRAMP and quantum roadmap is not an offset to mainframe franchise in structural decline with active fraud probe
| $8.25 |
| neutral |
| 52-Week Range Low | $197.77 | neutral |
| 52-Week Range High | $330.09 | neutral |
Support: 214.4 · 209 · 220 · 225.93 · 229.73 | Resistance: 237.5 · 238.5 · 245.07 · 250 · 252 · 258 · 262
IBM is in a post-traumatic recovery phase following a Jul 14 catastrophic downside gap (-25.2%) from $288.16 to $215.52. The stock has rallied ~18% from the July 23 low of $197.77 to close at $233.69, but bear market structure remains intact with all three moving averages stacked bearish (10 EMA < 50 SMA < 200 SMA) and price 11% below the 200 SMA at $262.64. Tactical indicators show short-term improvement: MACD has crossed above its signal line with histogram flipping positive (+1.80 from -9.77), RSI has recovered from oversold (29.18) to neutral (48.65), and ATR has collapsed ~50% from the Jul 14 panic spike of $16.75 to $8.25. Immediate resistance sits at $237.50–$238.50 (recent swing highs) and $245.07 (Bollinger upper band), with support at $229.73 (Bollinger middle) and $220.00 (psychological). Final recommendation: HOLD for existing positions; await cleaner structural confirmation—either a sustained close above $240 with RSI >55 or a successful retest of $220 support—before adding exposure.
Market Cap
$220.17B
PE Ratio (TTM)
20.74
Forward PE
17.75
PEG Ratio
2.41
Price to Book
6.39
EPS (TTM)
$11.27
Forward EPS
$13.16
Dividend Yield
2.85%
Beta
0.705
52-Week High
$332.46
52-Week Low
$199.19
50-Day Moving Avg
$248.97
200-Day Moving Avg
$266.72
Revenue (TTM)
$69.09B
Gross Profit
$40.14B
Gross Margin
~58.1%
EBITDA
$16.47B
EBITDA Margin
~23.8%
Net Income
$10.71B
Net Profit Margin
15.5%
Operating Margin
16.5%
Return on Equity (ROE)
34.5%
Return on Assets (ROA)
5.3%
Free Cash Flow (TTM)
$12.05B
FCF Margin
~17.4%
Dividend Coverage (FCF)
~1.9x
Total Assets
$152.10B
Total Liabilities
$117.56B
Total Equity
$34.45B
Total Debt
$65.27B
Net Debt
$54.82B
Cash & Equivalents
$7.17B
Short-term Investments
$0.96B
Current Ratio
0.79
Debt to Equity
188.97%
Net Debt to EBITDA
~3.3x
Goodwill
$74.60B
Intangibles
$13.95B
Treasury Stock
$170.93B
Retained Earnings
$155.94B
Working Capital
-$7.51B
Invested Capital
$96.44B
Q2 2026 Revenue
$17.16B
Q2 2026 Net Income
$2.17B
Q2 2026 Diluted EPS
$2.27
Q1 2026 Net Income
$1.22B
Q4 2025 Revenue
$19.69B
Q4 2025 Net Income
$5.60B
Q4 2025 Diluted EPS
$5.88
R&D (Q2 2026)
$2.31B
SG&A (Q2 2026)
$4.53B
CapEx (Q2 2026)
$383M
Debt Repayment (Q2 2026)
$4.21B
Q1 2026 Investing Outflow
$10.49B
Q2 2026 Quarterly Dividend
~$1.59B
Annualized Dividend
~$6.36B
Effective Tax Rate (Q2 2026)
12.6%
Q2 2026 Revenue YoY Growth
~+1.1%
Q2 2026 Net Income YoY Growth
~-1.3%
Forward EPS Growth
~17%
Strengths
Concerns
IBM presents a mixed fundamental profile with best-in-class 34.5% ROE and robust $12.05B TTM free cash flow supporting its 2.85% dividend yield, while the stock trades below both its 50-day and 200-day moving averages suggesting near-term technical weakness. The company's Q1 2026 acquisition expanded goodwill to $74.60B and raised leverage to ~3.3x Net Debt/EBITDA, though aggressive deleveraging with $4.21B Q2 debt repayment demonstrates capital discipline. With forward PE (17.75) below TTM PE (20.74) implying ~17% EPS growth expectations, IBM's AI/hybrid cloud transformation offers upside optionality, though investors should monitor goodwill impairment risk and liquidity metrics given negative working capital.
Macro: Risk-off environment on Aug 20 selloff driven by weak retail earnings (Walmart) and rising bond yields. Trump economic warfare rhetoric pushing yields and oil higher. Dow Jones triggered bearish signal. Tech broadly under pressure. Higher-for-longer Fed regime (86% no cuts in 2026) supports dollar but pressures long-duration tech valuations. US recession odds at 8% vs Japan 35% and UK 10%.